Tanshinone IIA inhibits gastric carcinoma AGS Cells through increasing p-p38, p-JNK and p53 but Reducing p-ERK, CDC2 and Cyclin B1 expression

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7097-7110

  Su, Chin Cheng ^a,b,c  

^a Department of Surgery   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

G2 M arrest; Gastric carcinoma AGS cells; MAPK; Tanshinone IIA

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 8; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; FAS ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TANSHINONE IIA; TUMOR NECROSIS FACTOR ALPHA; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; CCNB1 PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLANT EXTRACT; TANSHINONE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; MTT ASSAY; PROTEIN EXPRESSION; STOMACH CARCINOMA; WESTERN BLOTTING; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; M PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; CYCLIN B1; CYCLIN-DEPENDENT KINASES; DITERPENES, ABIETANE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; M PHASE CELL CYCLE CHECKPOINTS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLANT EXTRACTS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84918578695     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Che AJ, Zhang JY, Li CH, Chen XF, Hu ZD and Chen XG: Separation and determination of active components in radix Salviae miltiorrhizae and its medicinal preparations by nonaqueous capillary electrophoresis. J Sep Sci 27: 569-575, 2004.
2. Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359, 2005.
3. Su CC, Chen GW, Kang JC and Chan MH: Growth inhibition and apoptosis induction by tanshinone IIA in human colon adenocarcinoma cells. Planta Med 74: 1357-1362, 2008.
4. Su CC and Lin YH: Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med 22: 357-361, 2008.
5. Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med 25: 231-236, 2010.
6. Hou J, He J, Jin X, Hu T and Zhang Y: Study on optimisation of extraction process of tanshinone IIA and its mechanism of induction of gastric cancer SGC7901 cell apoptosis. Afr J Tradit Complement Altern Med 10: 456-458, 2013.
7. Xu M, Cao FL, Li NY, Liu YQ, Li YP and Lv CL: Tanshinone IIA reverses the malignant phenotype of SGC7901 gastric cancer cells. Asian Pac J Cancer Prev 14: 173-177, 2013.
8. Chen J, Shi DY, Liu SL and Zhong L: Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo. Oncol Rep 27: 523-528, 2012.
9. Dong X, Dong J and Peng G: Growth-inhibiting and apoptosisinducing effects of Tanshinone II A on human gastric carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 27: 706-709, 2007.
10. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
11. Gaur U and Aggarwal BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66: 1403-1408, 2003.
12. Molina JR and Adjei AA: The RAS/RAF/MAPK Pathway. J Thorac Oncol 1: 7-9, 2006.
13. Mossman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J Immunol Methods. 65: 55-63, 1983.
14. Bradford MM: A rapid and sensitive method for the quantization of microgram quantities of protein using the principle of proteindye binding, Anal Biochem 72: 248-254, 1976.
15. Chen HC, Hsieh WT, Chang WC and Chung JG: Aloe-emodin induced in vitro G2/M arrest of cell cycle in human promyelocytic leukemia HL-60 cells, Food Chem Toxicol 42: 1251-1257, 2004.
16. Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC and Chung JG: Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res 25: 971-979, 2005.
17. Lorca T, Labbe JC, Devault A, Fesquet D, Capony JP, Cavadore JC, Le Bouffant F and Doree M: Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 11: 2381-2390, 1992.
18. Wade Harper J and Stephen J: Elledge The role of Cdk7 in CAK function, a retro-retrospective Genes Dev 12: 285-289, 1998.
19. Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965, 2007.
20. Nordstrm E, Fisone G and Kristensson K: Opposing effects of ERK and p38-JNK MAP kinase pathways on formation of prions in GT1-1 cells. FASEB J 23: 613-622, 2009.
21. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
22. Rubinfeld H and Seger R: The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 31: 151-174, 2005.
23. Wagne EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
24. Kant S, Swat W, Zhang S, Zhang ZY, Neel BG, Flavell RA and Davis RJ: TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 25: 2069- 2078, 2011.
25. Gaur U and Aggarwal BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol 66: 1403-1408, 2003.
26. Wajant H: The Fas signaling pathway: more than a paradigm. Science 296: 1635-1636, 2002.